uniQure produces its AAV-based gene therapies in our own facilities with our proprietary manufacturing process, which uses insect cells and baculoviruses, a common family of harmless viruses found in invertebrates. An overview of our key patent portfolio can be found here.
Our facility in Lexington, Mass. is one of the largest, most versatile gene therapy manufacturing facilities in the world. uniQure has made significant investments in designing, constructing and equipping our facility with state-of-the-art laboratories and commercial-scale production capabilities. The facility, which was expanded in late 2019 from 55,000 square feet to 80,000 square feet, offers GMP production capabilities to support all of our existing programs, with flexibility to expand further.
uniQure is committed to manufacturing excellence in gene therapy, and we believe that our leading manufacturing capabilities provide us a significant competitive advantage in rapidly delivering gene therapies to patients.
In March 2017, uniQure was recognized by Frost & Sullivan as a 2017 Manufacturing Leadership Awards winner for outstanding achievement in Engineering & Production Technology Leadership.